Lumida
/CMPX
⌘K
Compass Therapeutics Inc.

Compass Therapeutics Inc.

CMPX
$2.05USD-2.38%-0.05 today

MARKET CAP

369.2M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$2
$7

AI Summary

Stalk
TrimMedium

CMPX remains in Stage 4 decline with price below declining EMAs and no base development. Long- and medium-term structures are bearish, while short-term timing is neutral as price consolidates near the flush‐low. Execution should be deferred until rallies into the broken EMA zone for selective trimming.

  • Tevesimig achieved 17.1% overall response rate and >20% survival, outperforming controls
  • Analyst consensus is Moderate Buy with $12.25 target implying 425.8% upside
  • Earnings Yield of –2.38% and weak profitability score signal financial strain
Full analysis →
Insider Trades23 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Apr 29, 2026BuyCMPXNeil LernerChief Accounting Officer15,000$1.89$369.2M-70.20%+27.33%$28.4K+3.92%Trim
Apr 29, 2026BuyCMPXNeil LernerChief Accounting Officer15,000$1.89$369.2M-70.20%+27.33%$28.4K+3.92%Trim
Apr 29, 2026BuyCMPXJonathan AndermanGeneral Counsel25,000$1.89$369.2M-70.20%+27.33%$47.3K+14.62%Trim
Apr 29, 2026BuyCMPXJonathan AndermanGeneral Counsel25,000$1.89$369.2M-70.20%+27.33%$47.3K+14.62%Trim
Feb 8, 2026SellCMPXThomas J. SchuetzCHIEF EXECUTIVE OFFICER36,687$6.52$369.2M-70.20%+27.33%$239.2K-0.55%Trim
Jan 9, 2026SellCMPXThomas J. SchuetzCHIEF EXECUTIVE OFFICER46,777$5.35$369.2M-70.20%+27.33%$250.3K-0.70%Trim
Jan 2, 2026BuyCMPXNeil LernerChief Accounting Officer62,500$5.17$369.2M-70.20%+27.33%$323.1K+8.28%Trim
Jan 2, 2026BuyCMPXBarry ShinCFO125,000$5.17$369.2M-70.20%+27.33%$646.3K+11.68%Trim
Jan 2, 2026BuyCMPXJonathan AndermanGeneral Counsel150,000$5.17$369.2M-70.20%+27.33%$775.5K+20.24%Trim
Jan 2, 2026BuyCMPXThomas J. SchuetzCEO250,000$5.17$369.2M-70.20%+27.33%$1.3M+2.96%Trim
Nov 16, 2025SellCMPXThomas J. SchuetzCHIEF EXECUTIVE OFFICER44,025$4.83$369.2M-70.20%+27.33%$212.6K-0.68%Trim
May 27, 2025BuyCMPXThomas J. SchuetzCHIEF EXECUTIVE OFFICER10,000$2.11$369.2M-70.20%+27.33%$21.1K+0.15%Trim
Apr 7, 2025BuyCMPXNeil LernerCHIEF ACCOUNTING OFFICER20,000$1.42$369.2M-70.20%+27.33%$28.4K+6.67%Trim
Apr 7, 2025BuyCMPXJonathan AndermanGen Counsel & Corporate Sec20,000$1.54$369.2M-70.20%+27.33%$30.8K+2000.00%Trim
Feb 8, 2025SellCMPXThomas J. SchuetzCEO41,687$3.50$369.2M-70.20%+27.33%$145.9K-0.64%Trim
Jan 9, 2025SellCMPXThomas J. SchuetzCEO58,054$1.86$369.2M-70.20%+27.33%$108.0K-0.88%Trim
Dec 9, 2024BuyCMPXBarry ShinCFO400,000$1.65$369.2M-70.20%+27.33%$660.0K+100.00%Trim
Feb 8, 2024SellCMPXThomas J. SchuetzPRESIDENT44,782$1.45$369.2M-70.20%+27.33%$64.9K-0.68%Trim
Feb 8, 2024SellCMPXVered Bisker-LeibCHIEF EXECUTIVE OFFICER49,198$1.45$369.2M-70.20%+27.33%$71.3K-1.55%Trim
Jan 9, 2024BuyCMPXThomas J. SchuetzPresident of R&D637,500$1.93$369.2M-70.20%+27.33%$1.2M+9.64%Trim
Jan 9, 2024BuyCMPXVered Bisker-LeibChief Executive Officer1,753,125$1.93$369.2M-70.20%+27.33%$3.4M+55.24%Trim
Nov 17, 2023SellCMPXThomas J. SchuetzCHIEF EXECUTIVE OFFICER44,025$1.50$369.2M-70.20%+27.33%$66.0K-0.73%Trim
Nov 17, 2023SellCMPXVered Bisker-LeibChief Operating Officer64,415$1.50$369.2M-70.20%+27.33%$96.6K-4.34%Trim